TY - JOUR
T1 - Gastrin Releasing Peptide Receptors-targeted PET Diagnostics and Radionuclide Therapy for Prostate Cancer Management
T2 - Preclinical and Clinical Developments of the Past 5 Years
AU - Dalm, Simone
AU - Duan, Heying
AU - Iagaru, Andrei
PY - 2024/7
Y1 - 2024/7
N2 - Prostate cancer (PC) remains one of the most prevalent cancer types accounting for 7.3% of all cancer cases in 2020.1 The 5 year survival rate of patients with local or regional disease is greater than 99%, but despite major developments made, the 5 year survival rate of advanced disease remains a mere 35%.2 Accordingly, research is focused on developing novel interventions for early detection and more effective treatment.
AB - Prostate cancer (PC) remains one of the most prevalent cancer types accounting for 7.3% of all cancer cases in 2020.1 The 5 year survival rate of patients with local or regional disease is greater than 99%, but despite major developments made, the 5 year survival rate of advanced disease remains a mere 35%.2 Accordingly, research is focused on developing novel interventions for early detection and more effective treatment.
UR - https://www.scopus.com/pages/publications/85190739426
U2 - 10.1016/j.cpet.2024.03.004
DO - 10.1016/j.cpet.2024.03.004
M3 - Review article
C2 - 38644111
AN - SCOPUS:85190739426
SN - 1556-8598
VL - 19
SP - 401
EP - 415
JO - PET Clinics
JF - PET Clinics
IS - 3
ER -
